Recent Quotes (30 days)

You have no recent quotes
chg | %

Alexander David Investments PLC  

(Public, LON:ADI)   Watch this stock  
Find more results forADI
0.120
-0.005 (-3.60%)
Apr 18 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 0.07 - 0.28
Open     -
Vol / Avg. 0.00/162,727.00
Mkt cap 680,017.00*
P/E     -
Div/yield     -
EPS 0.00*
Shares 564.33M
Beta     -
Inst. own     -
*GBP
Jun 21, 2013
Alexander David Investments PLC Annual General Meeting Add to calendar
  

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -116.77% -35.14%
Return on average equity -144.26% -51.20%
Employees 4 -
Carbon Disclosure Rating - -

Address

7th Floor, 45 Moorfields, Moorgate
LONDON, ENG EC2Y 9AE
United Kingdom - Map
+44-20-74489800 (Phone)
+44-20-71534921 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance
Discussion Group - Google Finance

Description

Alexander David Investments PLC (ADI), formerly ReGen Therapeutics PLC, is a United Kingdom-based investment company. ADI�s investment targets are small cap and special opportunities primarily in basic resources and oil and gas sectors. Such investments will focus on new and secondary equity issues but may also include some pre-initial public offer (IPO) investments. The Company will hold investments primarily for trading purposes, though some investments may be held for longer periods. The Company intends to act, primarily, as a passive investor. On February 18, 2011, the Company demerged its previous therapeutics business, to ReGen Therapeutics Limited. The portfolio of investments includes investments in AIM quoted companies in the basic resources and oil and gas sectors, including two companies in which ADI already held investments. On April 30, 2012, ADI acquired the portfolio of investments from Griffin Two Limited.

Officers and directors

Percy W. C. Lomax Executive Chairman of the Board, Chief Executive
Norman A. C. Lott Secretary, Non-Executive Director
Michael F. Hicks Non-Executive Director
David Scott Non-Executive Director